Drug Profile
Research programme: peptide-based immunotherapeutics - Bionor Holding
Alternative Names: Vacc CMV; Vacc Flu; Vacc HCV; Vacc HPV; Vacc-CMV (cytomegalovirus vaccine) - Bionor Holding; Vacc-Flu (universal influenza vaccine) - Bionor Holding; Vacc-HCV (hepatitis C vaccine) - Bionor Holding; Vacc-HIV; Vacc-HPV (human papillomavirus vaccine) - Bionor HoldingLatest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator Bionor Immuno
- Developer Bionor Holding
- Class Peptides; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cervical cancer; Cytomegalovirus infections; Hepatitis C; Human papillomavirus infections; Influenza virus infections
Highest Development Phases
- No development reported Cervical cancer; Hepatitis C; HIV infections; Human papillomavirus infections; Influenza virus infections
Most Recent Events
- 27 Dec 2022 Discontinued - Preclinical for HIV infections in United Kingdom (Parenteral)
- 28 Jul 2020 No recent reports of development identified for preclinical development in HIV-infections in United Kingdom (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cervical-cancer(Prevention) in Norway (Parenteral)